Deal Watch: AbbVie Partners With Gedeon Richter In Neuropsychiatry
Executive Summary
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
You may also be interested in...
Concert’s Patient-Reported Outcome Could Help Differentiate Its Alopecia Therapy
Concert’s CTP-543 would be second or third to market in alopecia areata, behind Lilly and likely Pfizer, but the biotech thinks its drug will have the best profile based on efficacy and patient satisfaction.
Concert’s CTP-543 Shows Advantages Over Lilly, Pfizer Candidates For Alopecia
Concert’s deuterated ruxolitinib analog is potentially third in line to market for alopecia areata, behind Lilly’s Olumiant and a Pfizer JAK3 inhibitor, but may be demonstrating a best-in-class profile.
Gedeon Richter Tipped For M&A As Cash Pile Rises
Gedeon Richter is keeping a keen eye on further business development opportunities, including M&A. The company is also continuing to tackle the impact of Russia’s invasion of Ukraine, observing that “there’s still not very much clarity on how the situation will evolve.”